

For immediate release

7 April 2020

TRAVIS DILLON JOINS TERRAGEN'S BOARD OF DIRECTORS

Coolum, QLD, 7 April 2020 – Australian ag-tech company Terragen Holdings Limited (ASX: TGH) ("Terragen"), is pleased to announce the appointment of Mr Travis Dillon to its Board of Directors effective 1 May 2020.

Mr Dillon brings to the Terragen Board of Directors extensive commercial and strategic expertise in the agricultural distribution channel. Mr Dillon was the CEO and Managing Director of Ruralco Holdings Limited ("Ruralco") until its acquisition by Nutrien in September 2019. Prior to becoming Ruralco's Managing Director in 2015, he was the Executive General Manager of Ruralco's Operations. Over a career in Agriservices, spanning nearly 3 decades, Travis has held many positions including Branch Manager, Agronomist and numerous Category Manager roles, experience which will bring relevant insights to the Terragen Board. Travis is a Non-Executive Director of Lifeline Australia.

In addition to joining the Board, Travis will provide support to Terragen's Sales and Marketing Team as an advisor.

A summary of the significant terms of Travis' appointment is presented in Attachment 1.

Terragen Chairman, Dr Paul Schober, said: "The staff and Board at Terragen are very pleased to welcome Travis and look forward to his contributions".

Mr Dillon commented: "There are exciting opportunities ahead for Terragen and I look forward to contributing to the Company's future."

About Terragen Holdings Limited

Terragen develops and markets a portfolio of biological technologies that use live microbes to address soil health and help boost the growth, productivity, welfare and resilience of farm production animals. The Company's aim is to reduce farmers' reliance on chemical-based fertilisers, pesticides and antibiotics.

Terragen believes that its biological technologies will help generate better outcomes for farmers and their crops and livestock and provide improved environmental outcomes that will be more acceptable to consumers.

Terragen has two products on the market in Australia and New Zealand: soil conditioner 'Great Land' and microbial feed supplement 'Mylo®'. Terragen is also developing veterinary medicines: Lactolin, a teat conditioner to maintain and improve the udders of lactating production animals, and Halo, an anti-inflammatory product to assist dairy cattle with mastitis and companion animals such as dogs with mobility impairments.

For further information, please contact:

Terragen Holdings Limited	Authorisation & Additional information:
Justus Homburg	This announcement was authorised by Justus
Managing Director & Chief Executive Officer	Homburg, the Managing Director of Terragen
+ 61 7 5446 1615	Holdings Limited.
media@terragen.com.au	

ATTACHMENT 1

SUMMARY OF TERMS OF TRAVIS DILLON'S APPOINTMENT

The key terms of Mr Dillon's appointment as Non-Executive Director are:

- i. **Role**: Non-Executive Director.
- ii. **Appointment date**: 1 May 2020.
- iii. **Term**: No fixed term.
- iv. **Termination**: By resignation of Mr Dillon or removal from office as a Director in accordance with the Company's constitution or Part 2D.3 of the Corporations Act 2001 (Cth).
- v. **Remuneration**: Mr Dillon shall be entitled to the following remuneration:
 - (a) \$36,000 per annum plus \$4,000 per annum for each Board sub-committee to which Mr Dillon is appointed; and
 - **(b)** A consultancy fee of \$78,000 per annum for assisting management with the development and implementation of the Group's commercialisation strategy.